Does a genetic variant in foxo3a predict a milder course of rheumatoid arthritis?

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1678-1681

  Van Steenbergen, H W ^a   Rantapaa Dahlqvist S ^b   Van Nies, J A B ^a   Berglin, E ^b   Huizinga, T W J ^a   Gregersen, P K ^c   Van Der Helm Van Mil, A H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 7; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR FKHRL1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; JOINT DESTRUCTION; META ANALYSIS (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UPREGULATION;

ANIMALS; ARTHRITIS, RHEUMATOID; CROHN DISEASE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MALARIA, FALCIPARUM; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84901624478     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38405     Document Type: Article

References (21)

1. Knevel R, Grondal G, Huizinga TW, Visser AW, Jonsson H, Vikingsson A, et al. Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2012; 71: 707-9.
2. De Rooy DP, Zhernakova A, Tsonaka R, Willemze A, Kurreeman BA, Trynka G, et al. A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 2013. E-pub ahead of print.
3. Knevel R, de Rooy DP, Zhernakova A, Grondal G, Krabben A, Steinsson K, et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum 2013; 65: 1684-93.
4. Lee JC, Espeli M, Anderson CA, Linterman MA, Pocock JM, Williams NJ, et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 2013; 155: 57-69.
5. Hedrick SM,. The cunning little vixen: Foxo and the cycle of life and death. Nat Immunol 2009; 10: 1057-63.
6. Turrel-Davin F, Tournadre A, Pachot A, Arnaud B, Cazalis MA, Mougin B, et al. FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum Dis 2010; 69: 755-60.
7. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
9. De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH,. Predicting arthritis outcomes: what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
10. Van der Heijde DM, van Riel PL, Gribnau FW, Nuver-Zwart IH, van de Putte LB,. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 1036-8.
11. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR,. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008; 35: 1002-8.
12. Larsen A,. Radiological grading of rheumatoid arthritis: an interobserver study. Scand J Rheumatol 1973; 2: 136-8.
13. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis: a genomewide study. N Engl J Med 2007; 357: 1199-209.
14. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F,. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
15. Wolfe F, Michaud K,. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) 2011; 50: 16-24.
16. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-201.
17. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-3.
18. Knevel R, Tsonaka R, le Cessie S, van der Linden MP, Huizinga TW, van der Heijde DM, et al. Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol 2013; 42: 182-9.
19. Van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009; 60: 2262-71.
20. James D, Young A, Kulinskaya E, Knight E, Thompson W, Ollier W, et al. Orthopaedic intervention in early rheumatoid arthritis: occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years. Rheumatology (Oxford) 2004; 43: 369-76.
21. Humphreys JH, Verstappen SM, Hyrich KL, Chipping JR, Marshall T, Symmons DP,. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013; 72: 1315-20.